Deerfield Management Company L.P. Series C Raises Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Deerfield Management Company L.P. Series C lifted its position in Twist Bioscience Co. (NASDAQ:TWST) by 1.7% in the 4th quarter, HoldingsChannel reports. The firm owned 23,827 shares of the company’s stock after purchasing an additional 403 shares during the quarter. Deerfield Management Company L.P. Series C’s holdings in Twist Bioscience were worth $1,107,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Van ECK Associates Corp lifted its holdings in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at approximately $34,000. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $43,000. US Bancorp DE raised its holdings in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares during the period. Finally, KBC Group NV grew its holdings in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares during the period.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 689 shares of the business’s stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the sale, the insider now owns 110,849 shares of the company’s stock, valued at approximately $4,173,464.85. The trade was a 0.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Chess sold 2,940 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now directly owns 18,173 shares in the company, valued at $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,931 shares of company stock valued at $898,856 over the last quarter. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $32.78 on Thursday. The firm’s 50-day moving average is $38.90 and its two-hundred day moving average is $43.82. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. Twist Bioscience Co. has a 12-month low of $31.56 and a 12-month high of $60.90. The stock has a market capitalization of $1.96 billion, a P/E ratio of -9.70 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Equities analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, Guggenheim restated a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.